Ribavirin
Ribavirin is a guanine derivative approved for treating Human
coronavirus (HCV) and respiratory syncytial virus (RSV), evaluated in
patients with SARS and MERS, but it has side effects, such as anaemia
might prove severe at high doses, [12] reported to be rapidly and
extensively absorbed following oral administration, and whether it could
offer sufficient potency against 2019-nCoV is uncertain [15].
Ribavirin, in high concentrations such as (Half- Effective Concentration
(EC50) = 109.50 μM, Half- Concentration (CC50) > 400 μM,
Selectivity Index (SI) > 3.65) was needed to minimize viral
infection [10] and, according to preliminary results, may prove to
be resistance to COVID-19.